β-受体阻滞剂治疗恶性室性心律失常的系统评价

A systematic evaluation of β-blockers in treatment of malignant ventricular arrhythmia

目的:系统评价β-受体阻滞剂治疗恶性室性心律失常的临床疗效及安全性。方法:电子搜索中国期刊全文数据库(CNKI,1979.01～2012.01)、Pubmed(1978～2012.01)、The Cochrane Library,搜集β-受体阻滞剂治疗恶性室性心律失常的随机对照试验,按照Cochrane协作网等的相关方法评价纳入文献质量和提取有效数据,应用RevMan5.0.25软件进行Meta分析。结果:共纳入4项研究,包括1586例患者。Meta分析结果显示:静脉应用β-受体阻滞剂是治疗恶性室性心律失常非常有效而且安全的方法,能有效地降低患者的死亡率(P<0.01,I2=0)OR=0.44,95%CI(0.32,0.60),未见严重不良反应报道。结论:β-受体阻滞剂治疗恶性室性心律失常能有效改善患者的生存率且相对安全。

Objective ： To evaluate the clinical effect and safety of β-blockers in treatment of malignant ventricular arrhythmia. Methods： We searched CNKI （January 1979 to January 2012） ,Pubmed（ 1978 to January 2012） , The Cochrane Library to identify randomized controlled trials （RCTs） about effects of β-Blockers on malignant ventricular arrhythmia. The methodological quality was assessed and the data was extracted according to the Cochrane Reviewer＇s Handbook and related methods. Meta-analyses were performed using RevMan 5.0.25 software. Results： Four eligible studies involving 1 586 patients were included. The results of meta-analyses showed that using intravenous β-blockers in malignant ventricu- lar arrhythmia could significantly reduce cardiac death and arrhythmic death or resuscitated cardiac arrest （ P 〈 0.01,12 = 0） OR =0.44,95%CI（0.32,0.60）. All eligible studies did not report any serious side effects about anisodamine. Conclusion： Using β-Blockers on malignant ventricular arrhythmia can improve patients＇survival and is relatively safe.